Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 112 publications.

D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623

Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730

Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S494. doi: 10.1016/j.jval.2024.10.2513

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the economic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S629. doi: 10.1016/j.jval.2024.10.3157

Khanji C, Nuabor W, Kim HK, Yubin SA, Kim R, Njue A. Systematic literature review of the humanistic burden of hemophilia A and B. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S613. doi: 10.1016/j.jval.2024.10.3082

Yubin Sohn A, Khanji C, Nuabor W, Gould T, Kim HK, Barrows SM, Herbel B, Njue A. Effect of adherence to hemophilia drug therapy on outcomes: a systematic literature review. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S634. doi: 10.1016/j.jval.2024.10.3181

Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S382. doi: 10.1016/j.jval.2024.10.1970

Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184

Copley-Merriman K, Miller-Wilson LA, Costello J, Schwinn J, Edwards Y. Evidence gap analysis of the burden of illness and treatment of myasthenia gravis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S384-5. doi: 10.1016/j.jval.2024.03.1792

Masaquel C, Miller-Wilson LA, D'Souza V, Schwinn J, Mina-Osorio P. Evidence gap analysis of the burden of disease in thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S389. doi: 10.1016/j.jval.2024.03.2461

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564

Petit I, Eliasson L, Romero B, Patel C, Di Rosa A, Quinn J. Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S309. doi: 10.1016/j.jval.2024.03.1955

Gildea L, Copley-Merriman C, Arvin-Berod C, Vande Walle K, Verheesen P, Stoykov I. Evidence gap analysis of the burden of illness and treatment of bullous pemphigoid. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S27. doi: 10.1016/j.jval.2023.09.141

Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Warttig S, Hartley L, Ling C. Understanding how health technology assessment bodies select medical technology for review: results of an online survey. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S432. doi: 10.1016/j.jval.2023.09.2258

D'Souza V, Gildea L, Mordin M, Long J, Kinderås M, Ling C, Warttig S, Hartley L. Differences and similarities of health economic evaluation for medical technologies by HTA bodies. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S438. doi: 10.1016/j.jval.2023.09.2287

Mordin M, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Warttig S, Hartley L. What evidence should medical technology companies expect HTA bodies to review? Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S431. doi: 10.1016/j.jval.2023.09.2254

Mordin M, Warttig S, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Hartley L. Digging into the medical technology HTA process in Tunisia. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S429. doi: 10.1016/j.jval.2023.09.2242

Langevin E, Lesage H, Juniper M. Invasive meningococcal disease economic burden: a comprehensive analysis. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S198. doi: 10.1016/j.jval.2023.09.1009

Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Clinical burden of patients with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S549-50. doi: 10.1016/j.jval.2023.09.2953

Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Economic burden of patients in the United States with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplment):S553. doi: 10.1016/j.jval.2023.09.2970

Lanne G, Kinderås M, Ling C, Brodtkorb TH. How much does TLV value rarity? A review of reimbursement decisions on orphan drugs in Sweden from 2017 through 2022. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S201. doi: 10.1016/j.jval.2023.09.1028

Kinderås M, Gildea L, Mordin M, Long J, D'Souza V, Ling C, Warttig S, Hartley L. Submission process and requirements of Nordic health technology assessment organisations for medical technologies: results of an online survey. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S435. doi: 10.1016/j.jval.2023.09.2272

Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619

Mordin M, Castro C, Gnanasakthy A. Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S325. doi: 10.1016/j.jval.2023.03.1852

Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S272-3. doi: 10.1016/j.jval.2023.03.1503

Fernandez M, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Burden of surgery in desmoid tumors. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S22. doi: 10.1016/j.jval.2023.03.117

Costello J, D'Souza V, Gildea L, Kinderås M, Ling C, Belisario JM, Warttig S. Process and requirements for submitting nonpharmaceutical medical technologies to health technology assessment authorities. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S386. doi: 10.1016/j.jval.2022.09.1915

D'Souza V, Copley-Merriman C. Analysis: first year of the new early access authorization in France. Poster presented at the ISPOR Europe 2022; November 6, 2022. [abstract] Value Health. 2022 Dec 1; 25(12):S342. doi: 10.1016/j.jval.2022.09.1691

Warttig S, D'Souza V. Analysis of health technology assessment (HTA) procedures and outcomes for orphan drugs. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S334-5. doi: 10.1016/j.jval.2022.09.1653

Warttig S, Ling C. Health technology assessment (HTA) methods for monoclonal antibodies for treatment and prevention of COVID-19. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S301. doi: 10.1016/j.jval.2022.09.1486

Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198

Fernandez M, Copley-Merriman C, Arvin-Berod C, Phillips G, Gelinas D, Weiss R, Hofman E, Tse A. Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S34. doi: 10.1016/j.jval.2022.09.164

Shim A, Trone D, Reynolds M, Odom D, Sherif B, Stopatschinskaja S. Patient reported outcomes (PRO) from phase 2 registrational trial of repotrectinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S421. doi: 10.1016/j.jval.2022.09.2093

Yang J, Masaquel C, Arvin-Berod C, Phillips G, Godar M, Desai M, Ayguasanosa J. Evidence gap analysis of the burden of illness and treatment of primary immune thrombocytopenia. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S19. doi: 10.1016/j.jval.2022.09.094

Banjara B, Poudel N, Garza KB, Westrick S, Whitley HP, Ngorsuraches S. Patients' preferences for newer second-line pharmacological agents in type 2 diabetes. Poster presented at the ISPOR 2022 Conference; May 15, 2022. National Harbor, MD. [abstract] Value Health. 2022 Jul; 25(7 Suppl):S566. doi: 10.1016/j.jval.2022.04.1475

D'Souza V, Njue A, Heyes A. DRG-based reimbursement and payment modalities for innovative remote patient monitoring technologies. Poster presented at the Virtual ISPOR Europe 2021; December 1, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Banjara B, Emory LA, Poudel N, Qian J, Ngorsuraches S. Patients' preferences for antihyperglycemic medications for type 2 diabetes: a systematic review of discrete choice experiment. Poster presented at the Virtual ISPOR 2021 Conference; May 17, 2021. [abstract] Value Health. 2021 Jun; 24(Suppl 1):S86. doi: 10.1016/j.jval.2021.04.444

D'Souza VK, Alderson D. Early access and targeted supply considerations in emerging markets. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2):S656. doi: 10.1016/j.jval.2020.08.1524

Stevenson A, Gildea L. A Medtech roadmap: new routes to market access in the UK NHS. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2):S576.

Noon K, Costello J, Krieger T, Rothwell B, Pearson I. Utility weight considerations in NICE immune checkpoint inhibitor oncology appraisals. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Molnar D, D'Souza V, Martin A. How the disease progression is captured in COPD models? A systematic literature review of disease and economic models. Poster presented at the 2020 Virtual ISPOR Europe; December 2020. [abstract] Value Health. 2020 Nov; 23(S2):S729-30. doi: 10.1016/j.jval.2020.08.1947

Reynolds M, Odom D, Richardson D, Hollis KA, Zhan L, Mitra D, McRoy L, Bowles S. Benefits and challenges of mobile health applications in prospective studies: learnings from the Madeline Study and literature. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S71-2. doi: 10.1016/j.jval.2020.04.1183

Castro C, Mordin M, Islam Z, Tu N, Hackshaw MD, Salas M. A review of non-disease specific health-related quality of life measures with reliability and validity evidence in patients with breast cancer. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S81.

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen S. Impact of neurofibromatosis type 1 and plexiform neurofibromas on patient-reported health-related quality of life. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S344. doi: 10.1016/j.jval.2020.04.371

Banjara B, Willke R, Guerino J, Ngorsuraches S. ISPOR top 10 HEOR trends: results from a best-worst scaling survey. Poster presented at the 2020 ISPOR Virtual Conference; May 16, 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S313. doi: 10.1016/j.jval.2020.04.1155

Banjara B, Kavookjian J. Interventions including motivational interviewing in adolescents with asthma: a systematic review. Poster presented at the 2020 ISPOR Virtual Conference; May 16, 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S349. doi: 10.1016/j.jval.2020.04.1331

Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Millar (Gildea) L, Stevenson A, Carter K. NICE medical technologies guidance - impact beyond the UK. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Heyes A, Millar (Gildea) L. Early dialogue with NICE and EUnetHTA: a UK perspective in a politically uncertain era. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).